key: cord-0729218-fviplzpn
authors: d'Alessandro, Miriana; Bergantini, Laura; Cameli, Paolo; Curatola, Giuseppe; Remediani, Lorenzo; Sestini, Piersante; Bargagli, Elena
title: Peripheral biomarkers’ panel for severe COVID‐19 patients
date: 2020-10-02
journal: J Med Virol
DOI: 10.1002/jmv.26577
sha: 105f3626a47523163287b7cededc4333f904055b
doc_id: 729218
cord_uid: fviplzpn

It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID‐19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID‐19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen‐6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non‐expensive bioindicators showed a good accuracy in discriminating between severe and non‐severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers’ panel, including lymphocyte cell counts and KL‐6, may be useful in the clinical management of severe COVID‐19 patients. This article is protected by copyright. All rights reserved.

To the Editor, It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID-19 (1-4). Pallotto C et al. analysed CD4/CD8 ratio in 38 hospitalized COVID-19 patients (reff). The authors propose an elevated CD4/CD8 ratio as a useful early predictive biomarker for development of critical illness in COVID-19 patients (5) . Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID-19 patients but we did not observe any significant alterations in CD4-and CD8-lymphocyte counts or CD4/CD8 ratio (4). On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen-6 (KL-6), which is a high molecular weight glycoprotein expressed by type 2 pneumocytes and released in the bloodstream after epithelial damage and reparative proliferation processes (6) (7) (8) . In particular, the Authors observed significantly higher serum KL-6 concentrations in severe COVID19 patients than those with milder disease (7).

This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients.

We retrospectively enrolled 54 patients (median age IQR, 64 (58-74) years; 61% males), hospitalized at COVID Unit of Siena University Hospital from March to May 2020.

Hospitalization criteria included diagnosis of COVID-19, vital organ involvement and nasopharyngeal swabs positive for SARS-CoV-2 nucleic acid by RT/PCR.

The study was conducted in compliance with the principles of the Declaration of Helsinki. This article is protected by copyright. All rights reserved.

Peripheral blood samples were obtained on admission before starting specific pharmacological treatment for COVID-19, and were processed by flow cytometry to lymphocyte immunophenotyping and chemiluminescence assay to KL-6 detection.

According to the need for intensive care unit (ICU) admission, mechanical ventilation or high-flow oxygen therapy, patients were divided into two groups: severe (n=14) and nonsevere (n=40).

The main characteristics of our COVID-19 population, including lymphocyte subset results and KL-6 concentrations, are reported in Table 1 .

Statistical analysis was performed using GraphPad Prism 8.0 software. Non parametric Oneway ANOVA test (Kruskal-Wallis test) and Dunn post-tests were used for multiple comparisons. The Mann-Whitney test was used to compare pairs of variables. The Chisquared test was used for categorical variables as appropriate. We also performed a logistic regression, using the severe group as dependent variable against non-severe patients, to assess the potential of serum markers in discriminating the two groups. Sensitivity, specificity, and positive and negative predicted values (PPV and NPV, respectively) were calculated for cut-off of the different variables.

The total number of lymphocytes (CD45 + ) was significantly lower in the severe than in the Thus, the present study confirmed that both NK cells and KL-6 are associated with more severe COVID19. In fact, we observed significantly higher serum KL-6 values, lower CD3-, CD8-and CD45-lymphocyte counts and NK cells in severe than in non-severe patients, in This article is protected by copyright. All rights reserved.

line with previous reports (4, 7) . Our findings support the hypothesis that NK population plays an important role as first-line defence with cytotoxic immune activity against SARS-Cov2 infection. Since it was depleted in severe patients with lung respiratory involvement requiring mechanical ventilation, larger and prospective studies would be worthwhile to confirm our results. Furthermore, the evidence of a significant increase of serum KL-6 in more critical patients is intriguing and suggests the potential prognostic value of this biomarker on this field. The combination of these validated, reproducible and non-expensive bioindicators showed a good accuracy in discriminating between severe and non-severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype.

Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers' panel, including lymphocyte cell counts and KL-6, may be useful in the clinical management of severe COVID-19 patients. AUC was 87.9% (95% CI 73-100, NPV 71.4% and PPV 84.6%, p=0.0063).

Clinical and Radiological Diagnosis of Non-SARS-CoV-2 Viruses in the Era of Covid-19 Pandemic

Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID-19 patients

Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study

Peripheral lymphocyte subset monitoring in COVID19 patients: a prospective Italian real-life case series

Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study

Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review

Serum KL-6 concentrations as a novel biomarker of severe COVID-19

Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes

This article is protected by copyright. All rights reserved